Trials / Completed
CompletedNCT04668495
Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor
Impact of Timing of Pharmacodynamic Assessments on Measures of Platelet Reactivity in Patients Undergoing Percutaneous Coronary Intervention Treated With Cangrelor
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 17 (actual)
- Sponsor
- University of Florida · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- —
Summary
This study is assessing the impact of timing of PD assessments on measures of platelet reactivity in patients undergoing PCI treated with cangrelor.
Detailed description
Cangrelor is characterized by reversible binding to the P2Y12 receptor and is promptly inactivated through dephosphorylation by ectonucleotidase leading to its very short plasma half-life. Consequently the timing at which PD assessments are performed after blood sample collection may impact measures of platelet reactivity in patients treated with cangrelor. We therefore hypothesize that measures of platelet inhibitory effects observed in cangrelor treated patients will reduce with time following blood sampling.
Conditions
Timeline
- Start date
- 2021-01-28
- Primary completion
- 2021-04-04
- Completion
- 2021-07-20
- First posted
- 2020-12-16
- Last updated
- 2021-09-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04668495. Inclusion in this directory is not an endorsement.